Expert consensus on quality control indicators for integrative medicine in ankylosing spondylitis (2023 version)

Abstract

The integrated treatment with Chinese and Western medicine plays an important role in the treatment of ankylosing spondylitis (AS), which can significantly relieve the patient's symptoms and improve quality of life. However, as a result of the lack of standardization of clinical management in some regions, the quality of AS treatment in China remains unoptimistic. In 2021, initiated by the Center for Integrative Medicine of China‐Japan Friendship Hospital, led by the traditional Chinese medicine department of rheumatology of China‐Japan Friendship Hospital, relying on the rheumatology branch of the Beijing Association of the integrating of traditional and Western medicine, and using the Delphi method, an expert consensus on “Quality Control Indicators for Integrative Medicine in Ankylosing Spondylitis” was established (Beijing Association of the Integrating of Traditional and Western Medicine Standardization Expert Consensus Filing Number: 2021Z031A2). The consensus revision updates the 2021 version by adding four items, which will provide a reference for the quality control of integrated traditional Chinese and Western medicine for AS in China and help improve the current diagnosis and treatment status of AS.

Keywords

ankylosing spondylitis / indicators / integrated Chinese and Western medicine / medical quality

References

[1] Rheumatology Branch of the Chinese Medical Association . Guidelines for diagnosis and treatment of ankylosing spondylitis. Chinese J Rheumatol. 2010; 14 (8): 557- 559.

[2] Fang Y , Liu J . Novel regulatory role of non-coding RNAs in ankylosing spondylitis. Front Immunol. 2023; 14: 1131355.

[3] Ben-Shabat N , Shabat A , Watad A , et al. Mortality in ankylosing spondylitis according to treatment: a nationwide retrospective cohort study of 5,900 patients from Israel. Arthritis Care Res. 2022; 74 (10): 1614- 1622.

[4] Dean LE , Jones GT , MacDonald AG , Downham C , Sturrock RD , Macfarlane GJ . Global prevalence of ankylosing spondylitis. Rheumatology. 2014; 53 (4): 650- 657.

[5] Song IH , Poddubnyy DA , Rudwaleit M , Sieper J . Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2008; 58 (4): 929- 938.

[6] Zhang J , Zhou Y , Ma Z . Multi-target mechanism of Tripteryguim Wilfordii Hook for treatment of ankylosing spondylitis based on network pharmacology and molecular docking. Ann Med. 2021; 53 (1): 1090- 1098.

[7] Wan R , Ji Y , Fan Y , et al. Efficacy and safety of Duhuo Jisheng decoction combined with Western medicine in the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Compl Ther Clin Pract. 2023; 51: 101739.

[8] Xie Y , Tu L , Zhang Y , et al. Efficacy and safety of Fengshi Gutong Capsule in patients with active ankylosing spondylitis: a 4-week randomized controlled, double-blinded, double-dummy trial. J Ethnopharmacol. 2022; 285: 114731.

[9] Ward MM , Deodhar A , Gensler LS , et al. 2019 update of the American college of rheumatology/spondylitis association of America/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019; 71 (10): 1599- 1613.

[10] Yan X . Handbook for Diagnosis and Treatment of Common Rheumatology. The Medicine Science and Technology Press of China; 2011.

[11] Rheumatology branch of the Beijing association of the integrating of traditional and western medicine . Consensus on long-term management of ankylosing spondylitis (2021). Chin J Integr Tradit West Med. 2021; 41 (12): 1426- 1434.

[12] Meng Z , Ma Y , Song S , et al. Economic implications of Chinese diagnosis-related group-based payment systems for critically Ill patients in ICUs. Crit Care Med. 2020; 48 (7): e565.

RIGHTS & PERMISSIONS

2024 The Author(s). Advanced Chinese Medicine published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.